SCHEMBL257222

SCHEMBL257222

Cc1c(C(=O)c2ccccc2)c(C)n(C)c1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.53
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 4/20 0.43
GAA P10253 1/20 0.43
SRC P12931 2/20 0.43
SRD5A2 P31213 1/20 0.42
HTT P42858 2/20 0.42
PTK2B Q14289 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA4 P48058 1/20 0.42
MYC P01106 1/20 0.41
GLA P06280 1/20 0.41
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197088 0.88 KMT2A (0.44) USP2MAPTLMNAHSD17B10SMN1; SMN2
SCHEMBL257221 0.83 KMT2A (0.69) USP2MAPTLMNASMN1; SMN2NPC1
SCHEMBL11016599 0.77 SRD5A2 (0.50) USP2MAPTLMNASMN1; SMN2NPC1
SCHEMBL4813653 0.76 USP2 (0.61) USP2MAPTLMNASMN1; SMN2NPC1
SCHEMBL19332153 0.75 RAB9A (0.48) USP2MAPTHSD17B10SMN1; SMN2NPC1
SCHEMBL5169856 0.75 ALDH1A1 (0.62) MAPTLMNAHSD17B10NPC1RAB9A
SCHEMBL11037236 0.74 ABCB11 (0.50) USP2MAPTLMNASMN1; SMN2KMT2A
SCHEMBL10920459 0.74 KMT2A (0.44) USP2MAPTLMNASMN1; SMN2NPC1
SCHEMBL16291319 0.72 SRC (0.67) KMT2ASRCEGFR
SCHEMBL1260620 0.72 MAPT (0.71) MAPTLMNAHSD17B10SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 USP2 4464/4885MAPT 3973/4885LMNA 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.